Objective Health Intelligence provide medical software as diagnostic medical devices. We have developed retinal (fundus) photograph analytical software - Spectra, complemented by the lower cost, standalone and portable Spectra Retineye. Spectra is one of only three software packages certified by the English National Diabetic Retinopathy (DR) Screening Programme. It has benefitted screening providers by seamless integration with patient records and ability to monitor over time. Providers reported improved throughput and attendance. Spectra highlights much more than just DR. In deployments to date, over 50% of urgent eye clinic referrals are for suspected non-diabetic retinopathies. Thus, Spectra detects reliable biomarkers for many conditions. The greatest causes of blindness (after cataracts) are glaucoma, age-related macular degeneration and DR. Spectra can detect early and treatable stages of these diseases, in particular low-pressure glaucoma missed by ocular pressure tests. New markets also exist for diabetic eye screening programmes (DESP) in countries lacking the resources of the UK NHS. Teleopthalmology (enabled by Spectra Retineye) could deliver these. Both Spectra and Spectra Retineye can deliver economic benefits:• Reducing need for expensive equipment and highly-qualified staff• Portability • Increased footfall in high-street optometrists from eye screening patients • Easier and lower cost of screening to patients • Reduced social security costs due to sight loss Spectra will deliver tremendous social benefits. Preventable, irreversible sight damage will become rarer, reducing sickness and caring burdens. Spectra Retineye, which is eminently adaptable to teleopthalmology will allow more delivery models. These will detect more problems earlier, including the 46% of diabetics who are unaware they have diabetes and thus risk severe sight loss and other health problems until they are identified. Fields of science natural sciencescomputer and information sciencessoftwaremedical and health sciencesclinical medicineophthalmologyglaucomamedical and health sciencesclinical medicineendocrinologydiabetesmedical and health sciencesclinical medicineophthalmologyretinopathymedical and health sciencesbasic medicinepharmacology and pharmacy Programme(s) H2020-EU.3.1. - SOCIETAL CHALLENGES - Health, demographic change and well-being Main Programme H2020-EU.3.1.3. - Treating and managing disease Topic(s) PHC-12-2015-1 - Clinical research for the validation of biomarkers and/or diagnostic medical devices Call for proposal H2020-SMEInst-2014-2015 See other projects for this call Sub call H2020-SMEINST-1-2015 Funding Scheme SME-1 - SME instrument phase 1 Coordinator HEALTH INTELLIGENCE LTD Net EU contribution € 50 000,00 Address Moston road saxon house CW11 3HL Sandbach United Kingdom See on map SME The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed. Yes Region North West (England) Cheshire Cheshire East Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Links Contact the organisation Opens in new window Website Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Other funding € 21 429,00
